IDEAYA Biosciences, Inc. Revenue
IDEAYA Biosciences, Inc. (IDYA) reported Revenue of $8.86 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-04
- IDEAYA Biosciences, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $8.86M.
- IDEAYA Biosciences, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $6.56M.
- IDEAYA Biosciences, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $10.88M, a 55.37% increase year-over-year.
- IDEAYA Biosciences, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $207.83M.
- IDEAYA Biosciences, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $218.71M, a 3024.43% increase from fiscal 2024.
- IDEAYA Biosciences, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $7.00M, a 70.07% decline from fiscal 2023.
- IDEAYA Biosciences, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $23.39M, a 54.08% decline from fiscal 2022.
- IDEAYA Biosciences, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $50.93M, a 82.28% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.86M 10-Q · filed 2026-08-04 | $15.42M 10-Q · filed 2026-08-04 | $26.29M derived: sum of 3 quarters · filed 2026-08-04 | $234.13M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $6.56M 10-Q · filed 2026-05-05 | $17.44M derived: sum of 2 quarters · filed 2026-05-05 | $225.27M derived: sum of 3 quarters · filed 2026-05-05 | |
| 2025-12-31 | $10.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $218.71M derived: sum of 2 quarters · filed 2026-02-17 | $218.71M 10-K · filed 2026-02-17 | |
| 2025-09-30 | $207.83M 10-Q · filed 2025-11-04 | $207.83M 10-Q · filed 2025-11-04 | ||
| 2024-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $7.00M derived: sum of 2 quarters · filed 2026-02-17 | $7.00M derived: sum of 3 quarters · filed 2026-02-17 | $7.00M 10-K · filed 2026-02-17 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-04 | $0.00 derived: sum of 2 quarters · filed 2024-11-04 | $0.00 10-Q · filed 2024-11-04 | $3.92M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $3.92M derived: sum of 3 quarters · filed 2026-02-17 | $11.96M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | $3.92M derived: sum of 2 quarters · filed 2026-02-17 | $11.96M derived: sum of 3 quarters · filed 2026-02-17 | $15.50M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $3.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $11.96M derived: sum of 2 quarters · filed 2026-02-17 | $15.50M derived: sum of 3 quarters · filed 2026-02-17 | $23.39M 10-K · filed 2026-02-17 |
| 2023-09-30 | $8.04M 10-Q · filed 2024-11-04 | $11.58M derived: sum of 2 quarters · filed 2024-11-04 | $19.46M 10-Q · filed 2024-11-04 | $23.48M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $3.54M 10-Q · filed 2024-08-06 | $11.42M 10-Q · filed 2024-08-06 | $15.45M derived: sum of 3 quarters · filed 2025-02-18 | $45.15M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $7.88M 10-Q · filed 2024-05-07 | $11.90M derived: sum of 2 quarters · filed 2025-02-18 | $41.60M derived: sum of 3 quarters · filed 2025-02-18 | $47.45M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $4.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $33.72M derived: sum of 2 quarters · filed 2025-02-18 | $39.57M derived: sum of 3 quarters · filed 2025-02-18 | $50.93M 10-K · filed 2025-02-18 |
| 2022-09-30 | $29.70M 10-Q · filed 2023-11-07 | $35.55M derived: sum of 2 quarters · filed 2023-11-07 | $46.91M 10-Q · filed 2023-11-07 | $49.87M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $5.85M 10-Q · filed 2023-08-10 | $17.21M 10-Q · filed 2023-08-10 | $20.17M derived: sum of 3 quarters · filed 2024-02-20 | $29.15M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $11.36M 10-Q · filed 2023-05-09 | $14.32M derived: sum of 2 quarters · filed 2024-02-20 | $23.30M derived: sum of 3 quarters · filed 2024-02-20 | $32.05M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $11.94M derived: sum of 2 quarters · filed 2024-02-20 | $20.69M derived: sum of 3 quarters · filed 2024-02-20 | $27.94M 10-K · filed 2024-02-20 |
| 2021-09-30 | $8.98M 10-Q · filed 2022-11-08 | $17.73M derived: sum of 2 quarters · filed 2022-11-08 | $24.98M 10-Q · filed 2022-11-08 | $35.55M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | $8.76M 10-Q · filed 2022-08-15 | $16.00M 10-Q · filed 2022-08-15 | $26.57M derived: sum of 3 quarters · filed 2023-03-07 | $35.54M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | $7.25M 10-Q · filed 2022-05-10 | $17.82M derived: sum of 2 quarters · filed 2023-03-07 | $26.79M derived: sum of 3 quarters · filed 2023-03-07 | |
| 2020-12-31 | $10.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $19.54M derived: sum of 2 quarters · filed 2023-03-07 | $19.54M 10-K · filed 2023-03-07 | |
| 2020-09-30 | $8.97M 10-Q · filed 2021-11-15 | $8.97M 10-Q · filed 2021-11-15 | ||
| 2019-12-31 | $0.00 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |